Chen J T, Yamashiro T, Shimizu Y, Kuo T C, Nakayama K, Teshima H, Hirai Y, Hamada T, Fujimoto I, Yamauchi K
Department of Gynecology, Cancer Institute Hospital, Tokyo.
Nihon Sanka Fujinka Gakkai Zasshi. 1988 May;40(5):534-40.
Renal toxicity following intraperitoneal (ip) CDDP therapy after laparotomy in twenty patients with ovarian cancer was examined. Four patients had renal toxicity. Patients who received CDDP at a dose of 150 mg (2/2) had a statistically higher incidence of toxicity than those who received less than 100 mg (2/18) (p less than 0.05). Patients who underwent ip therapy on the same day as laparotomy had a statistically higher incidence of the toxicity (4/15) than those underwent it on the fourth day after (0/5) (p less than 0.05). Renal toxicity was revealed in the mean urine volume of 1,100 ml on the day of therapy, but the toxicity did not appeared in those with a mean urine volume of 2,131 ml, whose volume was statistically different (p less than 0.01). These data suggest maintenance of renal blood flow during CDDP treatment plays an important role in preventing renal toxicity even following ip therapy. By investigating preoperative laboratory data, it is seen that patients with FDP values higher than 32 micrograms/ml have a higher risk of renal toxicity.
对20例卵巢癌患者剖腹手术后腹腔注射顺铂（CDDP）治疗后的肾毒性进行了检查。4例患者出现肾毒性。接受150mg剂量CDDP的患者（2/2）毒性发生率在统计学上高于接受剂量小于100mg的患者（2/18）（p<0.05）。与剖腹手术同一天接受腹腔内治疗的患者毒性发生率（4/15）在统计学上高于在术后第四天接受治疗的患者（0/5）（p<0.05）。治疗当天平均尿量为1100ml的患者出现肾毒性，但平均尿量为2131ml的患者未出现毒性，二者尿量在统计学上有差异（p<0.01）。这些数据表明，即使在腹腔内治疗后，CDDP治疗期间维持肾血流对预防肾毒性起着重要作用。通过研究术前实验室数据发现，纤维蛋白降解产物（FDP）值高于32μg/ml的患者发生肾毒性的风险更高。
